Novalar Pharmaceuticals Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novalar Pharmaceuticals Inc.
China’s Hengrui In-Licenses AMD Antibody Program From X-Body Biosciences
Hengrui becomes the first Chinese manufacturer to in-license an early stage MAb from a Western biopharma as it looks to develop an age-related macular degeneration therapy that could compete with Novartis/Roche’s Lucentis and Bayer/Regeneron’s Eylea.
China’s Hengrui In-Licenses AMD Antibody Program From X-Body Biosciences
Hengrui becomes the first Chinese manufacturer to in-license an early stage MAb from a Western biopharma as it looks to develop an age-related macular degeneration therapy that could compete with Novartis/Roche’s Lucentis and Bayer/Regeneron’s Eylea.
Sanofi-Aventis and Novalar file OraVerse in certain EU countries
Sanofi-Aventis and Novalar Pharmaceuticals have filed OraVerse (phentolamine mesylate) for the reversal of local anaesthesia for the acceleration for normal sensation and function following routine dental procedures in the UK, Germany, Italy, France and Spain.
US paediatric panel to review adverse events for four proton pump inhibitors
The US FDA's paediatric advisory committee will meet on 21 June to discuss paediatric-focused safety reviews for 13 drugs, including four proton pump inhibitors.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Site Specific
- Other Names / Subsidiaries
-
- Novocol Pharmaceutical of Canada, Inc
- Novalar®
- OraVerse
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice